Alvotech SA (ALVO)
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic area...
- Open
- 5.000
- High
- 5.265
- Low
- 4.980
- Prev. Close
- 4.950
- Volume
- 1.25M
- Turnover
- 6.47M
- Avg Price
- 5.175
- Bid/Ask Ratio
- --
- Amplitude
- 5.76%
- 52wk High
- 9.250
- Volume Ratio
- 1.53
- Turnover Ratio
- 1.10%
Alvotech SA Analyst Rating
View moreForecast & Rating
Aug 24, 2026Price forecast
$6.0015.61%
Forecast & RatingBuy
7analysts
- Strong buy57.14%
- Buy14.29%
- Hold14.29%
- Sell0.00%
- Strong sell14.29%
News
- StockTitan · 1 day ago, 07:30 PM
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations | ALVO Stock News
- PUBT · Aug 27 at 07:01 AM
Alvotech executives to speak at Morgan Stanley Global Healthcare Conference fireside chat
- Market Beat · Aug 24 at 10:00 AM
Alvotech (NASDAQ:ALVO) Shares Gap Up - What's Next?
- benzinga_article · Aug 24 at 09:22 AM
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday
- Simplywall · Aug 22 at 02:39 AM
Why Alvotech (ALVO) Is Up 9.2% After $150 Million Lotus Biosimilar Deal And 2026 Update
- Weekly Review · Aug 22 at 01:55 AM
Weekly Recap | Alvotech SA +9.25%, full-year guidance reaffirmed
